Prot #M13-813: A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification

Project: Research project

Project Details

StatusFinished
Effective start/end date5/17/16 → 5/17/19

Funding

  • AbbVie Inc. (Prot #M13-913)